Sugi Predict

Sugi Predict / Compounds / SCHEMBL2392328

SCHEMBL2392328

SCHEMBL2392328

COC(=O)c1cc(Cl)ccc1C=O

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.51
▸ NR4A2 P43354 2/20 0.49
▸ SLC6A4 P31645 1/20 0.49
▸ SLC6A3 Q01959 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.48
▸ PLA2G2A P14555 2/20 0.46
▸ ERN1 O75460 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ HPGD P15428 2/20 0.45
▸ GLA P06280 1/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ HTT P42858 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HCRTR1 O43613 1/20 0.42
▸ HCRTR2 O43614 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31098827 1.00 ABL1 (0.56) ABL1RXFP1NR4A2SLC6A4SLC6A3
SCHEMBL2420654 0.86 ABL1 (0.60) ABL1RXFP1NR4A2SLC6A4SLC6A3
SCHEMBL16008419 0.85 ABL1 (0.54) ABL1RXFP1NR4A2SLC6A4SLC6A3
SCHEMBL27577339 0.81 ALDH1A1 (0.50) ABL1RXFP1NR4A2SLC6A4SLC6A3
SCHEMBL25106844 0.81 CYP46A1 (0.50) NR4A2TDP1ERN1ALDH1A1HPGD
SCHEMBL18373091 0.81 ALDH1A1 (0.55) TDP1ERN1ALDH1A1HPGDKDM4E
SCHEMBL7014396 0.81 ALDH1A1 (0.55) ERN1ALDH1A1HPGDGLAKMT2A
SCHEMBL6420720 0.80 ABL1 (0.49) ABL1RXFP1NR4A2SLC6A4SLC6A3
SCHEMBL6420725 0.80 ABL1 (0.49) ABL1RXFP1NR4A2SLC6A4SLC6A3
SCHEMBL6100118 0.80 ABL1 (0.70) ABL1RXFP1NR4A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 — — US disclosed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 — — EP disclosed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 — — US disclosed
CN-119143773-B Preparation method of indolone spiro isochromanone derivative 山东第二医科大学 2025-01-28 — — CN disclosed
CN-114981265-B Compounds of formula (I) CTXT私人有限公司 2025-01-03 — — CN disclosed
CN-119143773-A Preparation method of indolone spiro isochromanone derivative 山东第二医科大学 2024-12-17 — — CN disclosed
US-12084437-B2 Halo-substituted piperidines as orexin receptor modulators ASTRAZENECA AB (SE) 2024-09-10 — — US disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 — — US disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 — — US disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 — — WO disclosed
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2013-10-24 — — US disclosed
WO-2013142307-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-09-26 — — WO disclosed
WO-2013142307-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-09-26 — — WO disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
EP-2516009-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES Novartis AG (CH) 2012-10-31 — — EP disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones MDM4, MDM2, TP53 ABL1 141/4885RXFP1 2809/4885NR4A2 136/4885
US-12415785-B2 Compound modulators of sting STING1, IRF3, MAVS ABL1 2874/4885RXFP1 2029/4885NR4A2 1505/4885
US-12084437-B2 Halo-substituted piperidines as orexin receptor modulators HCRTR2, HCRTR1, OPRD1 ABL1 3654/4885RXFP1 153/4885NR4A2 260/4885
US-20260132112-A1 COMPOUNDS STING1, IRF3, CGAS ABL1 2303/4885RXFP1 501/4885NR4A2 736/4885
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES MDM4, MDM2, TP53 ABL1 141/4885RXFP1 2809/4885NR4A2 136/4885
US-20230062932-A1 COMPOUNDS STING1, IRF3, MAVS ABL1 2459/4885RXFP1 1910/4885NR4A2 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.